Taken together, the data suggest that MM patients with early high levels of SLAMF7 expression on NK cells in blood or BM have shorter PFS regardless of subsequent therapy, and this correlation was particularly evident in ND patients. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.